TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)
Brief Summary: This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e. the maximum trial duration (up to max. 148 weeks) will depend on the accrual of major adverse cardiovascular events (MACE) in this trial and the remaining research programme. The incidence of MACE will be monitored throughout the trial which will be terminated according to plan when pre-specified stopping criteria are met.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2
B: Arm Label: linagliptin; Type: EXPERIMENTAL; Interventions: Drug: linagliptin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: linagliptin; Assigned to Arm(s): linagliptin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Semaglutide 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide 1.0 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide placebo 0.5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Semaglutide placebo 1.0 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 0.5 mg | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 1.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Semaglutide placebo 0.5 mg, Semaglutide placebo 1.0 mg
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)
Brief Summary: This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e. the maximum trial duration (up to max. 148 weeks) will depend on the accrual of major adverse cardiovascular events (MACE) in this trial and the remaining research programme. The incidence of MACE will be monitored throughout the trial which will be terminated according to plan when pre-specified stopping criteria are met.


Options:
A: Arm Label: Semaglutide 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide 1.0 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide placebo 0.5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Semaglutide placebo 1.0 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 0.5 mg | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 1.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Semaglutide placebo 0.5 mg, Semaglutide placebo 1.0 mg
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenograstim (GRANOCYTE)=GCSF, Drug: Sitagliptin (Januvia) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride (NaCl) 0.9 %, Drug: Gelatin | Intervention Type: DRUG; Name: Lenograstim (GRANOCYTE)=GCSF; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sitagliptin (Januvia); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride (NaCl) 0.9 %; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Gelatin; Assigned to Arm(s): 2
C: Arm Label: 1.5 mg Dulaglutide; Type: EXPERIMENTAL; Interventions: Drug: Dulaglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dulaglutide; Assigned to Arm(s): 1.5 mg Dulaglutide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Exenatide Once Weekly; Type: EXPERIMENTAL; Interventions: Drug: Exenatide Once Weekly | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Exenatide Once Weekly; Assigned to Arm(s): Exenatide Once Weekly | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Decision Making Among Treatment Alternatives for Abnormal Uterine Bleeding (AUB)
Brief Summary: The purpose of this study is to determine if using a computer survey about preferences for treatment of abnormal uterine bleeding (AUB) is useful and if it will improve patient satisfaction with clinical care and decision making. This study is a two-part study. The first pilot tests the computerized tool to ensure it is understood by patients, then the second part is a randomized study (computerized tool versus usual care) to see if improvements are made in satisfaction and if there are reductions in decision regret.


Options:
A: Arm Label: DECISION+ Program; Type: EXPERIMENTAL; Interventions: Behavioral: Decision+ program (to improve optimal drug prescription for ARI) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision+ program (to improve optimal drug prescription for ARI); Assigned to Arm(s): DECISION+ Program
B: Arm Label: Adaptive Conjoint Analysis; Type: EXPERIMENTAL; Interventions: Other: Adaptive Conjoint Analysis | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Adaptive Conjoint Analysis; Assigned to Arm(s): Adaptive Conjoint Analysis
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Bowel cancer screening decision aid | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Bowel cancer screening decision aid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Other: Australian Government Bowel Cancer Screening booklet | Intervention Type: OTHER; Name: Bowel cancer screening decision aid; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Bowel cancer screening decision aid; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Australian Government Bowel Cancer Screening booklet; Assigned to Arm(s): 3
D: Arm Label: Care coordinator + Decision Support Software; Type: EXPERIMENTAL; Interventions: Other: Care Coordinator + Decision Support Software | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Care Coordinator + Decision Support Software; Assigned to Arm(s): Care coordinator + Decision Support Software | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 4 Exercise Training in Aspects of Fatigue in Patients Receiving Dialysis Therapy
Brief Summary: The purpose of the current study is to investigate whether changes in patients' sleep quality and quantity will be followed by improvements in parameters related to physical and mental fatigue in patients receiving hemodialysis therapy.

More specific, the current project will investigate the effect of a 9 months intradialytic exercise training in aspects related to fatigue, quality of life and depression.


Options:
A: Arm Label: Home systolic blood pressure (SBP) <140 mmHg; Type: EXPERIMENTAL; Interventions: Drug: Anti-Hypertensive medications, Procedure: Dry Weight Adjustment | Arm Label: Pre-dialysis SBP <140 mmHg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-Hypertensive medications, Procedure: Dry Weight Adjustment | Intervention Type: DRUG; Name: Anti-Hypertensive medications; Assigned to Arm(s): Home systolic blood pressure (SBP) <140 mmHg, Pre-dialysis SBP <140 mmHg | Intervention Type: PROCEDURE; Name: Dry Weight Adjustment; Assigned to Arm(s): Home systolic blood pressure (SBP) <140 mmHg, Pre-dialysis SBP <140 mmHg
B: Arm Label: Intra-dialysis yoga; Type: EXPERIMENTAL; Interventions: Behavioral: Intradialysis-yoga | Arm Label: Educational program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational program | Intervention Type: BEHAVIORAL; Name: Intradialysis-yoga; Assigned to Arm(s): Intra-dialysis yoga | Intervention Type: BEHAVIORAL; Name: Educational program; Assigned to Arm(s): Educational program
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis; Assigned to Arm(s): Intervention
D: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: No exercise; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual Treatment | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise training | Intervention Type: OTHER; Name: Usual Treatment; Assigned to Arm(s): No exercise

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: IPS-MA - a Randomized Clinical Trial Examining the Effect of a Modified IPS Intervention in Addition to Treatment As Usual Versus Treatment As Usual Alone for Individuals with Mood or Anxiety Disorders
Brief Summary: The aim of the present study, is to evaluate the effect of a supported employment intervention, IPS-modified for people with mood and anxiety (IPS-MA) on employment or education, when offered to people with onset mood or anxiety disorders who are not likely to be able to return to work within three month.

The hypothesis is that the IPS-MA method is associated with a shorter recovery period and more people returning to work or education, compared to treatment as usual.


Options:
A: Arm Label: IPS-MA; Type: EXPERIMENTAL; Interventions: Behavioral: The IPS-MA method | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The IPS-MA method; Assigned to Arm(s): IPS-MA
B: Arm Label: Desvenlafaxine succinate sustained-release 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Desvenlafaxine succinate sustained-release 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine 60mg; Type: OTHER; Interventions: Drug: Duloxetine 60 mg/day | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 50 mg | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Duloxetine 60 mg/day; Assigned to Arm(s): Duloxetine 60mg
C: Arm Label: Tree Theme Method ® (TTM) intervention; Type: EXPERIMENTAL; Interventions: Other: Tree Theme Method ® (TTM) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Tree Theme Method ® (TTM); Assigned to Arm(s): Tree Theme Method ® (TTM) intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Low impact exercise | Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low impact exercise; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Recovery After Laparoscopic Hysterectomy With Deep Neuromuscular Blockade and Low Intra-abdominal Pressure
Brief Summary: The purpose of this study on laparoscopic hysterectomy is to investigate postoperative pain. Patients are allocated to either deep neuromuscular blockade and low intra-abdominal pressure (8 mmHg) or moderate neuromuscular blockade and usual intra-abdominal pressure (12 mmHg).

Primary hypothesis:

Deep neuromuscular blockade and low intra-abdominal pressure (8 mmHg) reduces postoperative pain compared to moderate neuromuscular blockade and intra-abdominal pressure (12 mmHg).


Options:
A: Arm Label: Pulmonary recruitment maneuver; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary recruitment maneuver | Arm Label: Intraperitoneal normal saline infusion; Type: EXPERIMENTAL; Interventions: Procedure: Intraperitoneal normal saline infusion | Arm Label: combined group; Type: EXPERIMENTAL; Interventions: Procedure: combined group | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Control group | Intervention Type: PROCEDURE; Name: Pulmonary recruitment maneuver; Assigned to Arm(s): Pulmonary recruitment maneuver | Intervention Type: PROCEDURE; Name: Intraperitoneal normal saline infusion; Assigned to Arm(s): Intraperitoneal normal saline infusion | Intervention Type: PROCEDURE; Name: combined group; Assigned to Arm(s): combined group | Intervention Type: PROCEDURE; Name: Control group; Assigned to Arm(s): Control group
B: Arm Label: Deep neuromuscular blockade; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rocuronium | Arm Label: Moderate neuromuscular blockade; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Rocuronium; Assigned to Arm(s): Deep neuromuscular blockade | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Moderate neuromuscular blockade
C: Arm Label: pulmonary recruitment maneuver; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary recruitment maneuver | Arm Label: intraperitoneal normal saline; Type: EXPERIMENTAL; Interventions: Procedure: Intraperitoneal normal saline | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Control group | Intervention Type: PROCEDURE; Name: Pulmonary recruitment maneuver; Assigned to Arm(s): pulmonary recruitment maneuver | Intervention Type: PROCEDURE; Name: Intraperitoneal normal saline; Assigned to Arm(s): intraperitoneal normal saline | Intervention Type: PROCEDURE; Name: Control group; Assigned to Arm(s): Control group
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Recruitment manouver | Intervention Type: PROCEDURE; Name: Recruitment manouver; Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Multicenter Placebo-controlled Trial on the Effect of Adalumumab on Vascular Inflammation in Patient With Moderate to Severe Psoriasis
Brief Summary: This study is a double-blinded randomized multicenter placebo controlled trial to determine the effect of adalimumab on vascular inflammation (ascending aorta and carotides) in patients with moderate to severe psoriasis.


Options:
A: Arm Label: Group Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Adalimumab, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Group Adalimumab, Placebo Group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Group
B: Arm Label: Bimekizumab cohort; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Bimekizumab Escape arm; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab Escape arm, Bimekizumab cohort | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Bimekizumab cohort, Placebo
C: Arm Label: LAS41008; Type: EXPERIMENTAL; Interventions: Drug: LAS41008 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LASW1835; Type: ACTIVE_COMPARATOR; Interventions: Drug: LASW1835 | Intervention Type: DRUG; Name: LAS41008; Assigned to Arm(s): LAS41008 | Intervention Type: DRUG; Name: LASW1835; Assigned to Arm(s): LASW1835 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: M1095 (Sonelokimab) 30mg; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 60mg; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 120mg - regimen 1; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 120mg - regimen 2; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: Placebo / M1095 (Sonelokimab) 120mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: M1095 (Sonelokimab), Drug: Placebo | Arm Label: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Intervention Type: DRUG; Name: M1095 (Sonelokimab); Assigned to Arm(s): M1095 (Sonelokimab) 120mg - regimen 1, M1095 (Sonelokimab) 120mg - regimen 2, M1095 (Sonelokimab) 30mg, M1095 (Sonelokimab) 60mg, Placebo / M1095 (Sonelokimab) 120mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / M1095 (Sonelokimab) 120mg | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Multicenter Placebo-controlled Trial on the Effect of Adalumumab on Vascular Inflammation in Patient With Moderate to Severe Psoriasis
Brief Summary: This study is a double-blinded randomized multicenter placebo controlled trial to determine the effect of adalimumab on vascular inflammation (ascending aorta and carotides) in patients with moderate to severe psoriasis.


Options:
A: Arm Label: Group Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Adalimumab, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Group Adalimumab, Placebo Group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Group
B: Arm Label: Secukinumab (AIN457) 75 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 150 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 300 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Placebo s.c.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Secukinumab (AIN457), Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab (AIN457); Assigned to Arm(s): Placebo s.c., Secukinumab (AIN457) 150 mg s.c., Secukinumab (AIN457) 300 mg s.c., Secukinumab (AIN457) 75 mg s.c. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c.
C: Arm Label: Induction Single Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Induction Monthly Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Induction Early Loading Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Placebo Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): Induction Single Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Monthly Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Early Loading Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Dose
D: Arm Label: Active Treatment (10 mg) BID / Placebo BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment (10 mg) BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment (5 mg) BID / Placebo BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment (5 mg) BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (10 mg) BID / Placebo BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (10 mg) BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (5 mg) BID / Placebo BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (5 mg) BID

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Multicenter Placebo-controlled Trial on the Effect of Adalumumab on Vascular Inflammation in Patient With Moderate to Severe Psoriasis
Brief Summary: This study is a double-blinded randomized multicenter placebo controlled trial to determine the effect of adalimumab on vascular inflammation (ascending aorta and carotides) in patients with moderate to severe psoriasis.


Options:
A: Arm Label: Bimekizumab Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Adalimumab Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bimekizumab, Drug: Adalimumab, Other: Placebo | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Adalimumab Arm, Bimekizumab Arm 1, Bimekizumab Arm 2 | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab Arm | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Adalimumab Arm, Bimekizumab Arm 1, Bimekizumab Arm 2
B: Arm Label: Group Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Adalimumab, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Group Adalimumab, Placebo Group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Group
C: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Immediate Methotrexate Cessation; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Gradual Reduction of Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Drug: Methotrexate | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Gradual Reduction of Methotrexate, Immediate Methotrexate Cessation | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Gradual Reduction of Methotrexate

Answer: B